Table 1.
Baseline characteristics of patients (intent-to-treat population) randomized to receive subcutaneous IFNβ-1a or IFNβ-1b
| Baseline characteristic | IFNβ-1a (N = 65) | IFNβ-1b (N = 64) |
|---|---|---|
| Age, years |
|
|
| Mean (SD) |
40.26 (9.80) |
40.78 (9.56) |
| Median (range) |
40.0 (20–60) |
40.0 (19–59) |
| Female, n (%) |
46 (70.8) |
44 (68.8) |
| Race, n (%) |
|
|
| White |
55 (84.6) |
58 (90.6) |
| Black |
6 (9.2) |
5 (7.8) |
| Asian |
2 (3.1) |
0 |
| Other |
2 (3.1) |
1 (1.6) |
| BMI, kg/m2, mean (SD) |
29.66 (6.76) |
30.23 (8.35) |
| Classification of MS, n (%) |
|
|
| Poser criteria |
19 (29.2) |
17 (26.6) |
| McDonald criteria |
46 (70.8) |
47 (73.4) |
| Time since first signs and/or symptoms of MS (onset), years, mean (SD) |
4.51 (6.70) |
5.74 (6.66) |
| Time since MS diagnosis, years, mean (SD) |
1.01 (2.35) |
1.93 (4.02) |
| Patients with no relapse during the 12 months before informed consent, n (%) |
10 (15.4) |
14 (21.9) |
| Relapses per patient,a mean (SD) |
1.36 (0.52) |
1.30 (0.46) |
| Time since last relapse,a months, mean (SD) |
3.52 (2.94) |
4.01 (2.93) |
| Number of steroid courses required for relapses per patient,a mean (SD) |
0.53 (0.60) |
0.46 (0.50) |
| Patients who required ≥1 course of steroids,an (%) | 26 (47.3) | 23 (46.0) |
aBased on total number of patients with relapses during the 12 months before informed consent.
BMI, body mass index; IFN, interferon; MS, multiple sclerosis; SD, standard deviation.